Adoptive T-Cell Therapy for Cancer

Advances in Immunology

Volumn 130, Issue , 2016, Pages 279-294

  Yang, James C ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive cell therapy; Immunotherapy; Neoantigens; T cell transfer; Tumor antigens; Tumor infiltrating lymphocytes

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; PEMBROLIZUMAB; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CYTOKINE RELEASE; GENETIC ENGINEERING; HUMAN; MELANOMA; METASTATIC MELANOMA; MISMATCH REPAIR; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMATIC MUTATION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR REJECTION; ANIMAL; CELL CYCLE CHECKPOINT; CELL ENGINEERING; GENETICS; IMMUNOLOGY; MOUSE; MUTATION; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; ANTIGENS, NEOPLASM; CELL CYCLE CHECKPOINTS; CELL ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MUTATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 84956673758     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/bs.ai.2015.12.006     Document Type: Chapter

References (48)

1. American Association for Cancer Research Expanding the reach of anti-PD-1 therapy. Cancer Discovery 2015, 5:684-685.
2. Boon T., Cerottini J.C., Van den Eynde B., van der Bruggen P., Van P.A. Tumor antigens recognized by T lymphocytes. Annual Review of Immunology 1994, 12:337-365.
3. Brahmer J., Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Poddubskaya E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. The New England Journal of Medicine 2015, 373:123-135.
4. Brentjens R.J., Santos E., Nikhamin Y., Yeh R., Matsushita M., La P.K., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research 2007, 13:5426-5435.
5. Bronte V., Mocellin S. Suppressive influences in the immune response to cancer. Journal of Immunotherapy 2009, 32:1-11.
6. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:1914-1918.
7. Coulie P.G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M., et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:7976-7980.
8. Eshhar Z., Waks T., Gross G. The emergence of T-bodies/CAR T cells. Cancer Journal 2014, 20:123-126.
9. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:720-724.
10. Gajewski T.F., Meng Y., Blank C., Brown I., Kacha A., Kline J., et al. Immune resistance orchestrated by the tumor microenvironment. Immunological Reviews 2006, 213:131-145.
11. Gattinoni L., Zhong X.S., Palmer D.C., Ji Y., Hinrichs C.S., Yu Z., et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Medicine 2009, 15:808-813.
12. Goff S.L., Smith F.O., Klapper J.A., Sherry R., Wunderlich J.R., Steinberg S.M., et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: Analysis of tumors resected for TIL. Journal of Immunotherapy 2010, 33:840-847.
13. Herin M., Lemoine C., Weynants P., Vessiere F., Van P.A., Knuth A., et al. Production of stable cytolytic T-cell clones directed against autologous human melanoma. International Journal of Cancer 1987, 39:390-396.
14. Hinrichs C.S., Spolski R., Paulos C.M., Gattinoni L., Kerstann K.W., Palmer D.C., et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008, 111:5326-5333.
15. Jager E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jager D., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. The Journal of Experimental Medicine 1998, 187:265-270.
16. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
17. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Rivoltini L., Topalian S.L., et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:3515-3519.
18. Klebanoff C.A., Acquavella N., Yu Z., Restifo N.P. Therapeutic cancer vaccines: Are we there yet?. Immunological Reviews 2011, 239:27-44.
19. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., Restifo N.P. Sinks, suppressors and antigen presenters: How lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends in Immunology 2005, 26:111-117.
20. Knuth A., Danowski B., Oettgen H.F., Old L.J. T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin 2-dependent T-cell cultures. Proceedings of the National Academy of Sciences of the United States of America 1984, 81:3511-3515.
21. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
22. Krauthammer M., Kong Y., Ha B.H., Evans P., Bacchiocchi A., McCusker J.P., et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics 2012, 44:1006-1014.
23. Kvistborg P., Shu C.J., Heemskerk B., Fankhauser M., Thrue C.A., Toebes M., et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012, 1:409-418.
24. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
25. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine 2015, 372:2509-2520.
26. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine 2014, 371:1507-1517.
27. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
28. Muul L.M., Spiess P.J., Director E.P., Rosenberg S.A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. Journal of Immunology 1987, 138:989-995.
29. Park T.S., Groh E.M., Patel K., Kerkar S.P., Lee C.C., Rosenberg S.A. Expression of MAGE-A and NY-ESO-1 in primary and metastatic cancers. Journal of Immunotherapy 2016, 39(1):1-7.
30. Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Molecular Therapy 2011, 19:620-626.
31. Riddell S.R., Greenberg P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. Journal of Immunological Methods 1990, 128:189-201.
32. Robbins P.F., El-Gamil M., Li Y.F., Kawakami Y., Loftus D., Appella E., et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. The Journal of Experimental Medicine 1996, 183:1185-1192.
33. Robbins P.F., Kassim S.H., Tran T.L., Crystal J.S., Morgan R.A., Feldman S.A., et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: Long-term follow-up and correlates with response. Clinical Cancer Research 2015, 21:1019-1027.
34. Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Medicine 2013, 19:747-752.
35. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology 2011, 29:917-924.
36. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., et al. Gene transfer into humans-Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. The New England Journal of Medicine 1990, 323:570-578.
37. Rosenberg S.A., Kawakami Y., Robbins P.F., Wang R. Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy. Advances in Cancer Research 1996, 70:145-177.
38. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. The New England Journal of Medicine 1988, 319:1676-1680.
39. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research 2011, 17:4550-4557.
40. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Journal of the National Cancer Institute 1994, 86:1159-1166.
41. Scanlan M.J., Welt S., Gordon C.M., Chen Y.T., Gure A.O., Stockert E., et al. Cancer-related serological recognition of human colon cancer: Identification of potential diagnostic and immunotherapeutic targets. Cancer Research 2002, 62:4041-4047.
42. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012, 366:2443-2454.
43. Topalian S.L., Solomon D., Rosenberg S.A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. Journal of Immunology 1989, 142:3714-3725.
44. Tran E., Turcotte S., Gros A., Robbins P.F., Lu Y.C., Dudley M.E., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344:641-645.
45. Van Allen E.M., Miao D., Schilling B., Shukla S.A., Blank C., Zimmer L., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015, 350:207-211.
46. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De P.E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
47. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284.
48. Zhang L., Morgan R.A., Beane J.D., Zheng Z., Dudley M.E., Kassim S.H., et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clinical Cancer Research 2015, 21:2278-2288.